MODEL VERDICT
Basel Medical Group Ltd Ordinary Shares (BMGL)
Relative Valuation•Peer multiples, competitive benchmarking & quality-adjusted fair value
Basel Medical Group Ltd Ordinary Shares is currently trading at a 45.03% discount to its peer-implied fair value.
4 curated peers matched by business model, revenue composition, and market position
1 valuation metric · peer-median based
| Multiple | Current | Peer Median | vs Peers | Implied Price |
|---|---|---|---|---|
| P/BMarket value versus book equity. | 2.86x | 3.64x | Discount -21.47% | $11.32 |
How the model derives the final fair value from peer baselines and quality metrics
Opportunity: The stock is trading at a 31.04% discount to its quality-adjusted fair value of $9.96. To reach its estimated fair value, the stock would need to appreciate by 45% from its current price of $6.87.
Quality metrics trail the peer group, warranting a discount.
Quality adjustments are capped at ±15% (up to ±20% for financial services) to prevent runaway premiums. Based on trailing twelve months and multi-year CAGR data where available.
How current multiples rank vs 1 years of the stock’s own history
| Multiple | Current | Historical Median | Percentile | Status |
|---|---|---|---|---|
| P/B1 years of data | 2.86x | 6.87x | 0th | Below historical norm |
Basel Medical Group Ltd Ordinary Shares currently trades near the lowest valuation levels observed during the last 1 years.
Model-identified caveats to consider
BMGL has a limited relative valuation using curated peers; based mainly on P/B, it looks cheap versus peers.
Answers to common questions about BMGL's relative valuation and our methodology.
Basel Medical Group Ltd Ordinary Shares's fair value of $9.96 is the price at which the stock would trade if valued at the same multiples as its 4-company peer group, adjusted for differences in business quality. At $6.87, the stock trades at a +44.98% discount to fair value. This is a reference point, not a price target.
The 4 peers shown were selected based on business model similarity, revenue composition, and market position. Each peer was matched for comparable operations, not just industry label. Only companies with clean, usable financial data are included.
Basel Medical Group Ltd Ordinary Shares has challenges in combined ratio, and a quality score that warrants a 12% discount relative to its peer group. The Quality Adjustment section breaks down each driver.
No. This page provides an automated quantitative comparison of Basel Medical Group Ltd Ordinary Shares against its peers. It is not investment advice, a recommendation, or a solicitation. Valuation is only one factor in an investment decision — it does not account for growth catalysts, management quality, regulatory risk, or your personal financial situation.
A 44.98% discount is substantial. Large discounts may signal that the market is overlooking value, but they can also reflect genuine business challenges or structural headwinds. Review the Risk Factors and Historical Context sections to assess whether the gap is justified.
Valuation data is refreshed weekly based on the latest financial filings, market prices, and analyst estimates. Basel Medical Group Ltd Ordinary Shares's fair value, peer multiples, and quality scores will shift over time as new earnings are reported and stock prices change.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. Fair value estimates are model outputs under stated assumptions and should not be relied upon as the sole basis for any investment decision.